Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8750874 | Respiratory Investigation | 2016 | 5 Pages |
Abstract
A low starting dosage of afatinib might enable elderly or low PS patients with advanced refractory NSCLC to receive this drug as salvage therapy.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology and Microbiology (General)
Authors
Kosuke Kashiwabara, Hiroshi Semba, Shinji Fujii, Shinsuke Tsumura,